PMC:7029759 / 21458-21700 JSONTXT

{"project":"LitCovid-PubTator","denotations":[{"id":"475","span":{"begin":76,"end":85},"obj":"Species"},{"id":"476","span":{"begin":208,"end":216},"obj":"Species"}],"attributes":[{"id":"A475","pred":"tao:has_database_id","subj":"475","obj":"Tax:9606"},{"id":"A476","pred":"tao:has_database_id","subj":"476","obj":"Tax:9606"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"The downside of including the Fc domain is the need to use a more expensive mammalian cell production system to preserve proper glycosylation, which would decrease the turnaround time for getting the drug to patients in the outbreak scenario."}

{"project":"LitCovid-PMC-OGER-BB","denotations":[{"id":"T337","span":{"begin":33,"end":39},"obj":"SO:0000417"},{"id":"T336","span":{"begin":76,"end":85},"obj":"NCBITaxon:40674"},{"id":"T335","span":{"begin":86,"end":101},"obj":"GO:0006412"},{"id":"T334","span":{"begin":200,"end":204},"obj":"CHEBI:23888;CHEBI:23888"}],"text":"The downside of including the Fc domain is the need to use a more expensive mammalian cell production system to preserve proper glycosylation, which would decrease the turnaround time for getting the drug to patients in the outbreak scenario."}

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T124","span":{"begin":86,"end":90},"obj":"Body_part"}],"attributes":[{"id":"A124","pred":"fma_id","subj":"T124","obj":"http://purl.org/sig/ont/fma/fma68646"}],"text":"The downside of including the Fc domain is the need to use a more expensive mammalian cell production system to preserve proper glycosylation, which would decrease the turnaround time for getting the drug to patients in the outbreak scenario."}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T184","span":{"begin":30,"end":32},"obj":"http://purl.obolibrary.org/obo/CLO_0052676"},{"id":"T185","span":{"begin":59,"end":60},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T186","span":{"begin":86,"end":90},"obj":"http://purl.obolibrary.org/obo/GO_0005623"}],"text":"The downside of including the Fc domain is the need to use a more expensive mammalian cell production system to preserve proper glycosylation, which would decrease the turnaround time for getting the drug to patients in the outbreak scenario."}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T81","span":{"begin":200,"end":204},"obj":"Chemical"}],"attributes":[{"id":"A81","pred":"chebi_id","subj":"T81","obj":"http://purl.obolibrary.org/obo/CHEBI_23888"}],"text":"The downside of including the Fc domain is the need to use a more expensive mammalian cell production system to preserve proper glycosylation, which would decrease the turnaround time for getting the drug to patients in the outbreak scenario."}

{"project":"LitCovid-PD-GO-BP","denotations":[{"id":"T13","span":{"begin":128,"end":141},"obj":"http://purl.obolibrary.org/obo/GO_0070085"}],"text":"The downside of including the Fc domain is the need to use a more expensive mammalian cell production system to preserve proper glycosylation, which would decrease the turnaround time for getting the drug to patients in the outbreak scenario."}

{"project":"LitCovid-sentences","denotations":[{"id":"T138","span":{"begin":0,"end":242},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"The downside of including the Fc domain is the need to use a more expensive mammalian cell production system to preserve proper glycosylation, which would decrease the turnaround time for getting the drug to patients in the outbreak scenario."}